22.06.2021 • News

Distrupol Takes Lautrup Chemicals

Distrupol, a UK-based distributor of thermoplastics and elastomers, has acquired Lautrup Chemicals, a Danish polymers distributor. Financial terms were not disclosed.

Headquartered in Copenhagen, Lautrup Chemicals’ main market is in Scandinavia, but it is also present in Eastern and Southern Europe. The company maintains a chain of warehouses that it said are strategically located in its key markets. It also runs its own fleet of trucks.

Richard Orme, managing director of Distrupol, said the Chertsey, Surrey-based company was “looking forward to expanding the range and reach of our product and service offerings to customers across Europe.”

“The acquisition of the Lautrup Chemicals business by Distrupol further extends the presence of GPD and continues the execution of our growth strategy,” added GPD’s CEO, Paul Tayler.

Distrupol is an affiliate of GPD companies, following its acquisition in April by private equity group One Rock Capital Partners from previous owner and US-based multinational distributor Univar. Holding company GPD also owns Nexeo Plastics, acquired from Nexeo Solutions in March 2019, when the latter merged into Univar.   

Author: Elaine Burridge, Freelance Journalist

UK-based Distrupol has acquired Lautrup Chemicals, a Danish polymers...
UK-based Distrupol has acquired Lautrup Chemicals, a Danish polymers distributor, for an undisclosed sum. Headquartered in Copenhagen, Lautrup Chemicals’ main market is in Scandinavia, but it is also present in Eastern and Southern Europe. (c) Lautrup Chemicals

Interview

The UK Chemical Supply Chain
Trade and Competitiveness

The UK Chemical Supply Chain

The CBA, led by CEO Tim Doggett, is steering the UK chemical supply chain through trade uncertainty, sustainability pressures and logistics challenges, as he explains in this interview with CHEManager.

Expert Insights

ADCs for Precision Cancer Therapy
Comprehensive Insights into Antibody–Drug Conjugates

ADCs for Precision Cancer Therapy

Explore how antibody-drug conjugates are reshaping precision cancer therapy and discover what it takes to successfully develop, manufacture, and scale these complex biologics.

most read